Drug intelligence / Profile preview

SKiP-MD

Development stage: Preclinical
Lead developer: Skip Therapeutics
Modality: Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics

Overview

SKiP-MD is an antisense oligonucleotide (ASO) therapy being developed by SKiP Therapeutics for the treatment of muscular dystrophy. The drug is designed to restore normal splicing of pre-mRNA, addressing genetic mutations that lead to dysfunctional protein production. By utilizing a proprietary computational platform for target identification, SKiP-MD aims to correct aberrant splicing patterns and promote the expression of functional proteins. The program is currently in the preclinical stage of development.

Beyond the preview

Go deeper on SKiP-MD.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SKiP-MD.

Explore the full profile